Immatics announced a clinical data update from the dose escalation cohorts of the company’s ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T).
by eazee-designstudio
Partner Therapeutics, Inc. (PTx), announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications.
Proceeds will advance two lead xenotransplantation programs in kidney failure and type 1 diabetes into first-in-human studies.
